SCHEMBL17434315

SCHEMBL17434315

CCn1c(=O)c2cc(NC(=O)C=Cc3ccccc3)ccc2n(CC)c1=O

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DHFR P00374 3/20 0.56
▸ MCHR1 Q99705 2/20 0.53
▸ MMP1 P03956 5/20 0.49
▸ MMP2 P08253 5/20 0.49
▸ MMP9 P14780 5/20 0.49
▸ EGFR P00533 4/20 0.49
▸ MAOA P21397 2/20 0.49
▸ MAOB P27338 2/20 0.49
▸ NPY5R Q15761 3/20 0.48
▸ CA12 O43570 1/20 0.48
▸ CA9 Q16790 1/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.47
▸ RORC P51449 1/20 0.47
▸ DEGS1 O15121 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17434314 1.00 DHFR (0.56) DHFRMCHR1MMP1MMP2MMP9
SCHEMBL4726991 0.85 NPSR1 (0.66) NPY5RKDM4EALDH1A1MAPTNPSR1
SCHEMBL4726995 0.85 NPSR1 (0.66) NPY5RKDM4EALDH1A1MAPTNPSR1
SCHEMBL17433948 0.85 RORC (0.51) NPY5RKDM4EALDH1A1MAPTNPSR1
SCHEMBL17433946 0.85 RORC (0.51) NPY5RKDM4EALDH1A1MAPTNPSR1
SCHEMBL17434226 0.82 RORC (0.53) NPY5RKDM4EALDH1A1MAPTNPSR1
SCHEMBL17434228 0.82 RORC (0.53) NPY5RKDM4EALDH1A1MAPTNPSR1
SCHEMBL19669660 0.73 PARG (0.51) NPY5RKDM4EALDH1A1MAPTNPSR1
SCHEMBL17434372 0.73 RORC (0.58) NPY5RKDM4EALDH1A1MAPTRORC
SCHEMBL17434030 0.72 RORC (0.71) NPY5RKDM4EALDH1A1MAPTRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9834520-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-12-05 — — US disclosed
US-20160229814-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-08-11 — — US disclosed
EP-2975031-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-01-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229814-A1 HETEROCYCLIC COMPOUND RORB, RORC, RORA DHFR 489/4885MCHR1 754/4885MMP1 4106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback